Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EASL 2022 NASH01 Poster Now Available on Poster Session Website
https://www.postersessiononline.eu/173580348_eu/congresos/ILC2022/aula/preposter_439168274_3.png
Enjoy!
700mg/350mg NASH Data Abstract Available Now
PDF Download from ILC 2022
https://events-program.easl.eu/ilc2022/en-GB/ProgramSearch/DownloadAbstract/231073
Latest Todos Emerging Growth Conference Posted
Looking forward to reading these. Hoping they detail time since illness. The debate seems to revolve around active virus vs. anti-inflammatory. It's a bit of the tail wagging the dog, finding solutions before understanding the condition, but I am sure those using it are just grateful to be getting some relief!
I was thinking it was because a lot is going on behind the scenes
Recent Tweet stating he will be buying as soon as he is allowed
We are. Still a lot of MNPI, but getting less as time goes by so a window will open up and I will do so as I've stated before
— Gerald Commissiong (@G_Commish) May 20, 2022
It would be interesting to see comparisons for a biotech with as many indications as far along as CYDY. I am not sure if you have any comparisons but I haven't been able to find any? Perhaps another platform drug?
With regards to LHers, is the proposed MOA the anti-cytokine piece? As I understand it, they have yet to find replication competent virus in those suffering from the affliction, which I believe would leave nothing to cleave. Many testimonials that it is easing symptoms however.
Thank you! I look forward to seeing the results. I have a hunch investors will be happy.
Do you happen to know when the latest financials will be released? It will be very interesting to see the impact of selling the inventory of Tollovid Daily
Starting to really follow this company as things ramp up. Really impressed with the hiring of Greg Meiselbach. Seems like a solid choice given his regulatory experience in emerging markets with a strong background in Asia. I would hazard a guess that this isn't by accident given the high usage of gromwell root in TCM.
So, the terms are 100% of the face value of the bond? 6.5M bond for $6.5M? That sounds strange does it not? Or is the face value likely higher?
That almost sounds more like an escrow than doesn't it? I have always thought of a bond as requiring some percentage of the value. Interesting. Clearly they owe 6.5M in cash if that is what they are saying in the 10q but I am not sure I understand why.
So is the face value of the bond greater than 6.5M? I would have thought 6.5M due would be for a bond of much higher value.
This is the source of my confusion
https://www.nnasuretybonds.com/how-much-does-a-surety-bond-cost
How much money does one have to put down for a 6.5M surety bond? Does anyone know?
Excited to learn from the Jedi Master :) Thx for sharing with the rest of us trding!
Long Hauler Trial Posted
https://clinicaltrials.gov/ct2/show/NCT04678830?cond=long+hauler&draw=2&rank=1
Doesn't Transaction Code F mean that he just sold enough to cover the exercise cost/taxes? Perhaps this is part of his annual compensation plan or something along those lines? Form 4 Wikipedia
I think this video, although posted today, is from last fall. He mentions they will be injecting their first cancer patient soon.
https://twitter.com/WmHaseltine is his twitter
Pre-Print of Dr. Bruce Patterson's Paper is Available
https://www.medrxiv.org/content/10.1101/2020.05.02.20084673v1
About those 18 term sheets... I found that frustrating as well. Was the "premier investment bank" the CFO talked about one of the 18? It sounded like they were in an NDA with them... Could anyone who understands the steps in that process chime in to elaborate? If they are one of the 18, they really should have been clear about that as it shows progress towards a very important goal.
I have the same gripe with the cancer stats. For an investor such as myself, spouting off different stats for each patient makes it confusing. You worry they are cherry picking data. For 3 of the 4 shouldn't we have CTCs? I know the MIL is another story because of the different protocol, but why not say CTC for each patient?
gestalt2, I didn't appreciate the backstory of Cytodyn until you mentioned Allen and I did a google search. Wow! What a fascinating story.
https://www.huffpost.com/entry/hivaids-researcher-allen-_b_7764756
I am telling you, this will be a tv mini-series some day
Cytodyn Veterinarian LLC? I had seen this awhile back on one of the filings. I am not sure if this was related solely to Feline Immunodeficiency Virus (https://www.cytodyn.com/newsroom/press-releases/detail/11/cytodyn-elects-two-new-directors-and-appoints-new-chief) or if they had bigger plans.
Having lost a young golden retriever to lymphoma, it would be awesome if the same MOA works in canine/feline cancers as well.
The veterinary oncology market is forecasted to reach 1B in the next 5 years.
Went through proactive videos to check for time stamps yesterday...there are some that were after 4PM EST...it's still possible!
Watching the video over again, I was struck by the statement
"this company, we were assured and our attorney's check out everything for us, that it has nothing to do with that person [Shkreli]" at around 3:30ish
This seems to conflict with what the lawsuit alleges
"38. Since his incarceration in September 2017, Shkreli has remained in regular contact with Mulleady and Mithani through phone calls, emails, in-person visits, and potentially other means. From June to December 2019 alone, Shkreli exchanged 240 emails with Mulleady and 391 emails with Mithani. In these communications, Shkreli continues to discuss strategies to prevent generic competition to Daraprim, as well as other
matters of Vyera business strategy"
It would appear that we were in the dark about this influence despite our lawyers doing DD to ensure it wasn't the case. I guess only time will tell how many in Vyera and/or Phoenixus AG were aware of this alleged influence.
One question I have is why Vyera? Assuming the transgressions were carried out by Turing under the two defendants, wouldn't the goal of Turing becoming Vyera be to shelter the new business from lawsuits? Or is the changing of the name just for public perception?
I am thinking it was more to avoid saying anything definitive on behalf of the FDA, not unlike ending every post with "in my opinion"...I have noticed he says "hopefully" with anything FDA related. You can understand why most CEOs don't communicate quite as much...you really have to watch everything you say and balance sounding optimistic for the shareholders but reserved and hopeful regarding the regulator's decisions. Not an easy job!!
Rescheduled to 1/22?
From the registration...
Welcome ! To register for this exclusive online conference, please enter your details below. For those who can’t attend our live session, we’ll send you a video of the presentations. Details: - You can join our session by using a Mac, PC or a mobile device. AGENDA: 12:30 - NexTech AR Solutions Inc. (OTC: NEXCF) - CEO Evan Gappelberg PLEASE NOTE: CytoDyn (OTC: CYDY) presentation is re-scheduled for next Wednesday January 22, 12:30 EST We look forward to having CYDY CEO Dr. Nader Pourhassan present next week!
Count me in
Closing price today?
Not sure why, but it shows as 1.11 in my brokerage account now even though it showed 1.12 until 4:15 PM or so...but many sites seem to show 1.12 even now. Just curious why the discrepancy? TIA
I *think* he said they are in talks with his wife and that they are sharing data with them at the moment. Everyone "thinks its too good to be true" or something to that effect. Crossing my fingers he tries it and it works for him.
So excited to see what comes of these conferences this week. Even if we don't get a big announcement, just getting this story out there will be huge. The only way I have been able to comprehend the fact that so few people know about this drug or stock is the news has yet to get to the masses...my hope is that this week it gets to the masses.
Cancer has impacted so many of us, either personally or through people we know. Just the "hope" of something that works and has no serious side effects thus far is an incredibly powerful force that could really have a major impact. And assuming the tests continue to validate that "hope"...watch out! :)
I sent an email via the jeopardy website (https://www.jeopardy.com/contact). You can select "Alex Trebek" from the dropdown. I am not sure if it will get to him but perhaps if many of us do it, it will standout amid the noise and someone will bring it to his handler's attention? Maybe?
I have enjoyed that show for so many years, I felt like I at least wanted to say how much it meant to me and to pass on this potentially life saving information. Just wish there was a way to know that he received it. He obviously has to make the final call, but it would be such a shame if he never actually knew it existed.
Great article and thank you for sharing. Seems like there is a lot of money available for acquisitions.
I have seen a lot of numbers thrown around regarding buy out targets but in my search for details on this I saw this older article from 2016 (https://seekingalpha.com/article/4008095-bubble-stocks-top-takeover-premium-charts) I am not sure how to find more recent data, but given that Tobira was noted as an exceptionally high premium a few years ago at 498% I was wondering how things would play out in the BO scenario. Given that NP has said repeatedly that we will be double digits, it seems like we would have to see an increase in share price before we could get a BO offer that would be in that realm? Can anyone chime in with more recent stats? Or are we just such an anomaly that analysis of previous deals doesn't provide much insight?
Thank you so much for the detailed explanation. I continue to learn so much from this forum and am so excited to do my minuscule part as an investor to get this drug in the hand of patients.
One quick follow up question... From this paper, https://www.ncbi.nlm.nih.gov/pubmed/11556308, I gathered that chemokines are the mechanism by which we postulate cancer metastasizes. CCR5 is one such chemokine. If the macrophages around the tumor aren't expressing CCR5 do we understand what they are expressing? Is it a different chemokine?
Fascinating new world for me
Cancer Metastasis Question...
My background is not medicine so please forgive me if this is a ridiculous question, but reading up on cancer metastasis, I was curious what differentiates our drug from say metarrestin, which attacks the perinucleolar compartment (PNC) of cancer cells to disrupt metastases? If I understand, leronlimab only works with tumors where the macrophages express CCR5. Is metarrestin attacking the same problem from a different angle or are the two drugs attacking different types of tumors (i.e. would metarrestin work where leronlimab wouldn't)? Thanks in advance!
I hopped aboard the CYDY express this year and wanted to thank you all for your contributions to this community. This company has not been without its share of drama and your commentary (both positive and negative) have helped me understand the many facets of this investment. Very much looking forward to what 2020 will bring both for Cytodyn as a company and even more importantly the many people struggling with the maladies leronlimab targets. Thank you and happy holidays!!